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Intra-amniotic Candida albicans 
infection induces mucosal injury 
and inflammation in the ovine fetal 
intestine
Maria Nikiforou1,2, Esmee M.R. Jacobs2, Matthew W. Kemp3, Mathias W. Hornef4, 
Matthew S. Payne3, Masatoshi Saito3,5, John P. Newnham3, Leon E.W. Janssen1,2, 
Alan H. Jobe3,6, Suhas G. Kallapur3,6, Boris W. Kramer1,2,7 & Tim G.A.M. Wolfs2,7,8
Chorioamnionitis is caused by intrauterine infection with microorganisms including Candida albicans 
(C.albicans). Chorioamnionitis is associated with postnatal intestinal pathologies including necrotizing 
enterocolitis. The underlying mechanisms by which intra-amniotic C.albicans infection adversely 
affects the fetal gut remain unknown. Therefore, we assessed whether intra-amniotic C.albicans 
infection would cause intestinal inflammation and mucosal injury in an ovine model. Additionally, 
we tested whether treatment with the fungistatic fluconazole ameliorated the adverse intestinal 
outcome of intra-amniotic C.albicans infection. Pregnant sheep received intra-amniotic injections 
with 107 colony-forming units C.albicans or saline at 3 or 5 days before preterm delivery at 122 days of 
gestation. Fetuses were given intra-amniotic and intra-peritoneal fluconazole treatments 2 days after 
intra-amniotic administration of C.albicans. Intra-amniotic C.albicans caused intestinal colonization 
and invasive growth within the fetal gut with mucosal injury and intestinal inflammation, characterized 
by increased CD3+ lymphocytes, MPO+ cells and elevated TNF-α and IL-17 mRNA levels. Fluconazole 
treatment in utero decreased intestinal C.albicans colonization, mucosal injury but failed to attenuate 
intestinal inflammation. Intra-amniotic C.albicans caused intestinal infection, injury and inflammation. 
Fluconazole treatment decreased mucosal injury but failed to ameliorate C.albicans-mediated mucosal 
inflammation emphasizing the need to optimize the applied antifungal therapeutic strategy.
Preterm birth, which frequently results from intrauterine infection, represents a major cause of neonatal morbid-
ity and mortality1. Chorioamnionitis, defined as inflammation of the chorioamniotic membranes and amniotic 
fluid2, is commonly caused by ascending infection into the uterine cavity3,4. While numerous different bacterial 
species have been cultured from the amniotic fluid of affected human fetuses, Ureaplasma (UP), Fusobacterium 
and Mycoplasma are the most commonly isolated microorganisms2,5,6. Microbial growth within the amniotic 
cavity exposes the fetus to bacterial toxins and inflammatory mediators that cause a fetal inflammatory response 
syndrome (FIRS) that is associated with postnatal adverse outcomes in multiple fetal organs including the gas-
trointestinal tract7. Preterm infants exposed to chorioamnionitis present in the clinic with a wide spectrum of 
adverse intestinal consequences ranging from poor nutritional uptake and subsequent postnatal growth deficits8 
to severe, life-threatening gastrointestinal complications such as necrotizing enterocolitis (NEC)9,10.
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Emerging evidence from recent studies supports an association between fungi (in particular yeasts such as 
Candida spp.) and chorioamnionitis11–13. Although Candida albicans (C.albicans) can be a commensal organ-
ism in the female genital tract, chorioamnionitis with C.albicans can cause fetal death or fetal candidiasis with 
systemic manifestations including sepsis14–16. Treatment of C.albicans infection during pregnancy has been 
challenging17. Although fluconazole, the most commonly used anti-fungal agent, has been associated with 
teratogenicity when administered at high doses orally, during the first trimester of pregnancy18, clinical cases 
of C.albicans-mediated chorioamnionitis at later stages of gestation were successfully treated with oral and 
intra-amniotic (IA) fluconazole in the absence of reported adverse effects15.
We have previously used a translational ovine chorioamnionitis model and have shown that IA exposure 
to lipopolysaccharide (LPS), UP or inflammatory mediators induces intestinal inflammation and mucosal 
injury19–21. Amniotic fluid infection with C.albicans can result in a reservoir of this organism in the fetal bowel 
where potentially may induce gastrointestinal pathologies. However, the underlying mechanisms by which 
intrauterine infection with C.albicans may result in adverse intestinal effects remain substantially unexplored. 
Therefore, we utilized our chorioamnionitis model to assess whether IA C.albicans infection caused intestinal 
colonization, local invasive growth and mucosal intestinal inflammatory responses associated with tissue damage 
to the fetal gut. Additionally, we tested whether IA and intra-peritoneal fluconazole treatment would ameliorate 
the adverse effects of C.albicans-mediated chorioamnionitis on the fetal ovine gut.
Materials and Methods
Animals. All animal experiments were approved by the Animal Ethics Committee of the University of 
Western Australia (Perth, WA, Australia) and the Children’s Hospital Medical Center (Cincinnati, Ohio, USA). 
All experimental methods were performed in accordance with the approved guidelines and regulations.
Experimental design. All experimental procedures were performed as previously described22. Date-mated 
Merino sheep (Ovis aries) were randomly assigned to either 1) a control group (n = 6), which received an IA injec-
tion of saline, 2) an antifungal group (n = 3), which received fluconazole treatment only, 3) a 3d C.albicans group 
(n = 7), which received an IA injection of 107 colony-forming units (CFU) of C.albicans (all C. albicans inoculums 
prepared in sterile saline) 3 days before preterm delivery and IA injection of saline 1 day before delivery 4) a 3d 
C.albicans and 1d fluconazole group (n = 6), which received an IA injection of 107 CFU C.albicans 3 days before 
preterm delivery and fluconazole treatment 1 day before delivery or 5) a 5d C.albicans and 3d fluconazole group 
(n = 5), which received an IA injection of 107 CFU C.albicans 5 days before delivery and fluconazole treatment 3 
days before delivery (Fig. 1). Since an IA exposure to C.albicans for 5 days was previously shown to result in fetal 
mortality, our experimental setting does not contain a group of animals only exposed to C.albicans for 5 days22. A 
dose of 15 mg fluconazole was injected into the amniotic cavity and 15 mg was given by intra-peritoneal injection 
to the fetus. This route of administration was chosen because of the long half-life of fluconazole and its direct 
availability to the fetus through swallowing of the amniotic fluid. All injections were performed under ultrasound 
guidance. All fetuses were delivered surgically at 122 days (± 1 day) of gestation (term at ~147–150 days) simulat-
ing a preterm human delivery of approximately 32–34 weeks of gestation.
Fetuses and ewes were euthanized with an intravenous bolus of pentobarbital (100 mg/kg). Fetal terminal 
ileum was immediately collected, frozen in liquid nitrogen and stored in − 80. In addition, fetal terminal ileum 
was placed in cassettes and immerged in formalin for immunohistochemical stainings.
Antibodies. The following antibodies were used. Polyclonal rabbit antibody against human CD3 (catalog ref-
erence A0452, 1:1000); rabbit antibody against human myeloperoxidase (MPO, catalog reference A0398, 1:500) 
both from Dako, (Glostrup, Denmark). As secondary antibodies, biotin conjugated swine anti-rabbit (catalog 
Figure 1. Experimental design. Fetal sheep were given intra-amniotic (IA) C.albicans or saline at 3 or 5 
days before preterm delivery at 122 days of gestation. IA and intra-peritoneal fluconazole treatment was 
administered to the fetus 2 days after C.albicans infection. CA, C.albicans; d, day(s); Fluc, Fluconazole; GA, 
gestational age; n, number.
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reference E0353, 1:200) from Dako and peroxidase conjugated goat anti-rabbit (catalog reference 111-035-045, 
1:200) from Jackson (West Grove, PA) were used.
Blood cultures. C.albicans in blood cultures was detected as described previously22. Briefly, fetal blood was 
inoculated into culture vials and incubated at 37 °C for 72 hours. Every day, 1 ml sample was removed and sub-
cultured on sheep blood agar at 37 °C for 48 hours. C.albicans colonial morphology was confirmed by growth on 
Brilliance Candida Agar (Oxoid, Adelaide, Australia) as previously reported22.
Immunohistochemistry. Formalin-fixed paraffin-embedded fetal terminal ileum was cut in 4 μ m thick 
sections. Morphology was evaluated using hematoxylin-and-eosin (H&E)-staining and fungi were visualized 
with periodic acid Schiff (PAS) staining. Immunohistochemistry was performed as previously described23. After 
blocking the endogenous peroxidase activity and non-specific binding, sections were incubated with anti-MPO or 
anti-CD3 antibodies for either 1 hour or overnight, respectively. Thereafter, sections were washed and incubated 
with a secondary biotin (CD3) or peroxidase (MPO) conjugated antibody. Substrate staining for MPO was per-
formed with 3-amino-9-ethylcarbazole (AEC) from Invitrogen, (Bleiswijk, the Netherlands). CD3 immunoreac-
tivity was detected by using nickel-DAB from Dako, (Glostrup, Denmark). Nuclei were counterstained with either 
Nuclear Fast Red (CD3) or hematoxylin (MPO). CD3 and MPO expressing cells were counted per high power field 
(Magnification × 200) and the average number of positive cells in 5 high power fields of terminal ileum per animal 
is presented. Assessment of the sections was performed as previously described23. Briefly, the high power field was 
defined under the microscope, a picture was captured and subsequently cell counting was performed using Image J.
Quantitative Real Time PCR (qPCR). The mRNA expression level of cytokines was measured by qPCR 
as previously described24. Total RNA was isolated from 50 mg freshly frozen ileal tissue by Trizol/chloroform 
extraction using the SV Total RNA Isolation System (Promega, Madison, WI, USA) according to manufacturer’s 
guidelines. The samples were treated with RQ1 DNase (Promega, Madison, WI, USA) to eliminate genomic DNA 
contamination. The extracted RNA was tested for the presence of genomic DNA using ovine specific actin primers 
by PCR (Westburg Thermocycler, Leusden, the Netherlands) and analyzed with agarose gel electrophoresis. Briefly, 
PCR amplification was performed with DNA Taq Polymerase (Promega) at 95 °C for 5 minutes, followed by 34 
cycles at 95 °C for 30 seconds, 52 °C for 45 seconds and 72 °C for 30 seconds. The quality of PCR products was tested 
in a 1.2% agarose gel. Reverse transcription was performed with M-MLV Reverse transcriptase from Invitrogen, 
(Bleiswijk, the Netherlands) according to manufacturer’s guidelines using oligo(dT) primers. qPCR was performed 
with the SensiMix SYBR & Fluorescein Kit from GC Biotech B.V., (Alphen aan de Den Rijn, the Netherlands) using 
a LightCycler 480 from Roche Applied Science, (Almere, the Netherlands) according to manufacturer’s instruc-
tions. The PCR reactions were run with 10 ng of cDNA, in duplicates using the appropriate primers to specifically 
amplify the ovine gene transcript (Supplementary Table 1). Based on previous reports25,26, expression stability and 
expression level (Cq value ~20) of S15 across several ovine tissues (including the gut) which were tested in our 
laboratory, we concluded that S15 can serve as a good reference gene. The efficiency of the primers was tested by 
dilution experiments. The results were normalized to the S15 ribosomal protein (ovRPS15) as a housekeeping gene 
(with a Cq value of 20), and the mean fold change in mRNA levels relative to the control are presented.
Enzyme-Linked Immunosorbent Assay (ELISA). To quantify the degree of infection-induced damage 
to the intestinal epithelium, the concentration of intestinal fatty acid-binding protein (I-FABP) was measured 
in fetal plasma samples by ELISA as previously described27. Briefly, an Elisa plate was coated with 3 μ g/well of 
anti-human I-FABP monoclonal antibody for 24 hours. A dilution series of a known concentration of human 
recombinant I-FABP protein was used for a standard curve. Plasma samples were diluted two times and were 
incubated with biotin-conjugated polyclonal anti-human I-FABP antibody, followed by incubation with streptavi-
din peroxidase. After incubation with the substrate, the reaction in the samples was terminated by adding 1M 
of H2SO4 and the optical density was measured at 450 nm in a Thermo Electron Type 1500 Multiskan Spectrum 
Microplate Reader.
Statistical Analysis. Statistical analysis was performed using GraphPad Prism software (version v5.0; 
GraphPad Software Inc., La Jolla, CA, USA). Comparisons between groups were evaluated by non-parametric 
Kruskal Wallis tests followed by Dunn’s multiple comparisons tests. Differences between groups in the detection 
of C.albicans in fetal blood and gut were analyzed by Fisher’s Exact Test. Data are presented as mean ± standard 
deviation (SD). Differences were considered statistically significant at p < 0.05.
Results
Systemic effects of IA C.albicans administration. Blood cultures for C.albicans and plasma levels of 
IL-6 as shown previously22,28 are depicted in Table 1.
C.albicans in the fetal intestine. We evaluated whether C.albicans could be detected in the fetal gut tissue 
by histochemical PAS staining. C.albicans was found in fetal gut tissue in 6/7 (86%) animals that were exposed 
to C.albicans for 3 days. In contrast, C.albicans was detected only in 2/6 (33%) animals that were exposed to 
C.albicans for 3 days and were treated with fluconazole for 1 day and in 1/5 (20%) animals that were exposed to 
C.albicans for 5 days and were treated with fluconazole for 3 days (Table 1).
Importantly, C.albicans had generated hyphae and invasive growth of C.albicans hyphae were found within 
the intestinal villi (Fig. 2A) and in the lamina propria (Fig. 2B), and particularly in close proximity to or inside 
Peyer’s patches (PP) (Fig. 2C,D). C.albicans was not detected in control animals or animals that had only received 
fluconazole.
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C.albicans caused gut epithelial injury. Subsequently, we evaluated whether C.albicans exposure caused 
intestinal epithelial damage by measuring plasma I-FABP, an enterocyte-specific cytosolic protein that is released 
upon injury29,30. Significantly increased (p < 0.05) concentration of I-FABP was detected in plasma samples of 
animals that were infected with C.albicans for 3 days when compared to controls (Fig. 3). The elevated I-FABP 
levels were significantly prevented at 1 day after fluconazole treatment (Fig. 3). I-FABP levels were not changed 
in the fluconazole only group and 5d C.albicans plus 3d fluconazole treatment group when compared to control.
C.albicans induced infiltration of inflammatory cells in the fetal gut. We next assessed the accu-
mulation of MPO+ and CD3+ immune cells in the fetal gut by immunohistochemistry. Significantly increased 
(p < 0.05) numbers of MPO+ cells were found in animals exposed to C.albicans for 3 days as well as in animals 
that were exposed to C.albicans for 5 days followed by fluconazole for 3 days when compared with controls 
(Fig. 4). Similarly, significantly increased (p < 0.05) numbers of CD3+ T cells were detected in the fetal gut of 
animals that were exposed to C.albicans for 3 days when compared with controls (Fig. 5). Fluconazole treatment 
after C.albicans exposure did not prevent the accumulation of CD3+ lymphocytes in the fetal gut (Fig. 5C).
Control Fluconazole 3d C.albicans 3d C.albicans + 1d Fluc 5d C.albicans + 3d Fluc
Positive C.albicans blood culture 0/6 (0%) 0/3 (0%) 5/7 (71%)* OR: 28.6  95% CI (1.12–731.54)
5/6 (83%) *OR: 47.67  
95% CI (1.6–1422.69) 3/5 (60%)
Positive PAS staining for Candida in the gut 0/6 (0%) 0/3 (0%) 6/7 (86%)* * OR: 56.33  95% CI (1.92–1655) 2/6 (33%)
1/5 (20%)$ OR: 0.033  
95% CI (0.001–0.68)
IL-6 (ng/mL) N.D. N.D. 40 ± 45* ,# N.D. 19 ± 29
Table 1.  Detection of C.albicans in fetal blood and gut tissue, and IL-6 plasma levels. For the detection 
of C.albicans in blood cultures and gut, the results were analyzed by Fisher’s Exact Test. Data are presented as 
positive/total number of animals. For IL-6 results, differences between groups were analyzed by non-parametric 
Kruskal Wallis tests followed by Dunn’s multiple comparisons test. Data are presented as mean ± SD. * p < 0.05, 
* * p < 0.01 compared to control. #p < 0.05 compared to 3d C.albicans + 1d Fluc group, $p < 0.05 compared to 3d 
C.albicans. CI, confidence interval; Fluc, fluconazole; IL, interleukin; n, number; N.D., not detectable; OR, odds 
ratio; PAS, Periodic acid–Schiff.
Figure 2. Detection of C.albicans hyphae in the fetal gut tissue. Hyphae of C.albicans were detected in the 
fetal gut at 3 days after IA exposure to C.albicans. Hyphae were found in intestinal villi (A), lamina propria  
(B), adjacent to (C) and inside mucosal Peyer’s patches (D) 3 days after of IA exposure to C.albicans.
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C.albicans increased gut mRNA levels of pro-inflammatory cytokines. We further characterized 
the inflammatory response by evaluating mRNA levels of pro- and anti-inflammatory cytokines in total gut tissue 
specimens. C.albicans exposure for 3 days significantly increased the intestinal mRNA levels of TNF-α and IL-17 
(p < 0.05 for both) when compared to controls (Fig. 6A,B). The elevated TNF-α and IL-17 mRNA levels were not 
Figure 3. Concentration of I-FABP (pg/mL) in fetal plasma. Intra-amniotic C.albicans exposure for 3 days 
increased the I-FABP levels in the fetal plasma. I-FABP levels were decreased in animals that were treated with 
fluconazole for 1 day after IA exposure to C. albicans Data are presented as mean ± SD. * p < 0.05.
Figure 4. Number of MPO + cells in the fetal ileum. For each experimental group, intestinal sections of  
(A) control and animals that were exposed to C.albicans for 3 days (B) were stained by immunohistochemistry 
for MPO. For each experimental group, positive expressing cells of MPO (arrow) were counted and the mean 
cell counts per high power field per animal is indicated (C). Data are presented as mean ± SD. * p < 0.05. MPO, 
myeloperoxidase.
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decreased at 1 day after fluconazole treatment. No changes were found in the mRNA levels of animals that were 
exposed to C.albicans for 5 days and treated with fluconazole when compared with controls. Intereukin-10 is 
known to be produced by the host upon infection with C.albicans hyphae and increased levels of IL-10 have been 
associated with increased susceptibility to candidiasis31. The mRNA levels of IL-10 remained unaltered after IA 
exposure to C.albicans with or without fluconazole treatment when compared with controls (Fig. 6C). The intes-
tinal mRNA levels of IL-23 were significantly decreased in animals that were exposed to IA C.albicans infection 
for 5 days and treated with fluconazole compared to controls (Fig. 6D). No changes were detected in gut IL-23 
mRNA of the remaining groups.
Discussion
We have shown that IA exposure of fetal lambs to C.albicans resulted in an invasive C.albicans infection of the 
fetal gut tissue associated with epithelial injury and the induction of mucosal inflammation. At this stage, the 
described intestinal changes were accompanied by fungal translocation and systemic spread of C.albicans associ-
ated with systemic inflammation. Fluconazole treatment prevented systemic inflammation and C.albicans colo-
nization of the fetal gut in the majority of C.albicans exposed animals. In addition, administration of fluconazole 
decreased epithelial injury of the fetal gut without inhibiting intestinal inflammation.
Growth of C.albicans in its hyphal form in the gut tissue strongly suggests that the detected mucosal injury is a 
direct consequence of C.albicans infection and translocation through the intestinal epithelial barrier. Invasion of 
enterocytes is mediated by active penetration of C.albicans in which, the hyphal form of C.albicans was previously 
shown to be necessary for the invasive process and the concomitant epithelial injury32. Hyphae of C.albicans were 
also in close proximity to PP. Recent in vitro experiments have shown that in addition to active penetration of 
enterocytes, C.albicans can translocate the intestinal epithelium via endocytosis by microfold (M) cells. M cells 
are located at the follicle-associated epithelium (FAE) of the PP33. The identification of C.albicans hyphae both 
within intestinal villi and in close proximity to PP suggests that both routes of intestinal translocation might have 
contributed to the disease observed after IA administration of C.albicans.
Epithelial damage as indicated by increased circulatory I-FABP levels following C.albicans exposure is an 
absolute requirement for Candida dissemination to the bloodstream34,35. Consistently, intestinal colonization 
and the associated mucosal injury at 3 days after C.albicans infection resulted in candidemia. The gastrointestinal 
Figure 5. Number of CD3 + cells in the fetal ileum. For each experimental group, intestinal sections of  
(A) control and animals that were exposed to C.albicans for 3 days (B) were stained by immunohistochemistry 
for CD3. For each experimental group, positive expressing cells of CD3 (arrow) were counted and the mean cell 
counts per high power field per animal is indicated (C). Data are presented as mean ± SD. * p < 0.05. CD, cluster 
of differentiation.
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tract is considered to be the most frequently organ that is involved in systemic dissemination36 and systemic 
candidiasis is a major contributor to neonatal sepsis37. In addition to translocation through the intestinal barrier, 
C.albicans might have breached the mucosa in other mucosal organs exposed to amniotic fluid38.
Mucosal invasion of C.albicans in the fetal gut by 3 days after infection was associated with infiltration of 
immune cells and was paralleled by elevated intestinal levels of TNF-α and IL-17. Increased levels of these 
cytokines were measured in gastrointestinal and oral mucosal surfaces of mice colonized by C.albicans39–42. 
Importantly, induction of TNF-α and IL-17 after C.albicans infection has been previously reported to stimulate 
the recruitment of neutrophils at the site of infection43 as detected in our chorioamnionitis model. Neutrophils 
are believed to be fundamental in the process of phagocytosis against mucosal and disseminated C.albicans 
infection43. Additionally, IL-17 is considered to be essential in mucosal immunity against C.albicans infection, 
as increased levels of IL-17 promote inflammation and disease progression44. Th17 cells (a hallmark of IL-17 
production) are commonly involved in host defense against C.albicans in epithelial and mucosal surfaces as they 
express chemokine receptors which locate them in epithelial and mucosal regions45. Evaluating the expression of 
Th17-specific surface markers would be crucial to identify and important to unravel the precise defense mech-
anism of fetal intestinal Th17 cells against IA C.albicans infection. In addition, establishing the role of intestinal 
macrophages (a predominant source of TNF-α ) against C.albicans infection would provide more insight in the 
process of phagocytosis and the interplay between innate and adaptive immune responses. Unfortunately, con-
sidering the current study design and the intrinsic limitations of our model such as the lack of ovine specific 
reagents, these intestinal immunological responses against IA C.albicans infection cannot be studied in detail 
at this stage. Nevertheless, this animal model was used as the development of the fetal ovine intestine during 
gestation is similar to human and this large animal model allow us to administer therapeutics, in doses which 
could potentially be used in humans. Therefore, this model is an appropriate preclinical model to investigate gut 
complications after C.albicans-mediated chorioamnionitis and test the therapeutic potential of IA fluconazole 
treatment during gestation.
In the same animals, we have previously shown that fluconazole treatment administered 2 days after IA 
administration of C.albicans, temporally prevented systemic inflammation and reduced fetal mortality22,28. In the 
present study, fluconazole treatment initiated 2 days after C.albicans infection decreased C.albicans colonization 
Figure 6. Cytokine mRNA levels in total fetal ileal tissue. The inflammatory cytokines TNF-α (A), IL-17 
(B), IL-10 (C) and IL-23 (D) were assessed by qPCR and the values for each cytokine were normalized to 
ovRPS15 rRNA. Data are presented as mean ± SD. * p < 0.05. IL, interleukin; TNF-α , tumor necrosis-α ; qPCR, 
quantitative real time polymerase chain reaction.
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and epithelial injury of the fetal gut. Remarkably, although circulatory IL-6 levels returned to baseline levels 
after fluconazole treatment, C.albicans infection persisted in the bloodstream of these animals. Since fluconazole 
treatment after C.albicans infection transiently prevented chorioamnion and lung inflammatory changes22, we 
speculated that the decreased IL-6 levels in the fetal plasma following fluconazole treatment were mediated by the 
lung and/or chorioamnion46. Nevertheless, the exact cause of systemic inflammation induced by IA C.albicans 
administration requires further investigation.
The reduction of intestinal C.albicans colonization in fluconazole treated animals was not associated with 
reduced intestinal inflammation. Fluconazole inhibits fungal growth by compromising its cell wall integrity47,48, 
which maintains inflammation. In fact the treatment-induced fungal cell destruction might temporarily increase 
the concentration of immunostimulatory molecules. On the other side, the ongoing inflammatory response is 
considered essential to eradicate the fungus49,50.
We have previously shown that fluconazole treatment after C.albicans infection was inadequate to eliminate 
C.albicans from the amniotic fluid. Moreover, the inflammatory response in several fetal organs was only tem-
porarily decreased following anti-fungal treatment22. These previous results combined with current data indicate 
that future research is warranted to explore the efficacy of alternative timing, dosing and frequency of fluconazole 
treatment in the context of intrauterine C.albicans infection.
In conclusion, we have shown that IA exposure of fetal lambs to C.albicans resulted in gut colonization, 
mucosal translocation, tissue injury and inflammation. These adverse intestinal consequences are associated 
with C.albicans translocation to the bloodstream with signs of systemic inflammation which was previously 
shown22,28. Although we did not assess the postnatal consequences of these findings, gut inflammation and tissue 
injury in conjunction with systemic inflammation are all pathological features, which are associated with neona-
tal gastrointestinal pathologies. In line, we have previously reported that chorioamnionitis with a fetal systemic 
inflammatory response, is strongly associated with NEC51. In addition, a single fluconazole treatment prevented 
systemic inflammation and decreased intestinal injury whereas mucosal inflammation and dissemination of 
C.albicans in the bloodstream remained unaffected. Consequently, future studies should focus on optimizing a 
fluconazole-based therapeutic strategy to completely protect the fetal gut in the context of C.albicans-mediated 
chorioamnionitis.
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